Overview
- Samsung Electronics and Samsung C&T signed a binding letter of intent to work with Grail on introducing the Galleri multi-cancer early detection test in Asian markets.
- The companies committed $110 million at $70.05 per share, with the investment expected to close in early 2026.
- Samsung C&T obtained exclusive commercialization rights for Galleri in South Korea, with potential expansion to Japan and Singapore.
- Samsung is exploring integration of Grail’s genomic diagnostics and datasets with its AI, device ecosystem and Samsung Health platform for personalized care.
- GRAIL shares rose about 14% on Oct. 16 following the announcement, and the company plans to seek FDA approval next year.